250 related articles for article (PubMed ID: 18661414)
1. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
2. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
3. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
Folkert VW; Michael B; Agarwal R; Coyne DW; Dahl N; Myirski P; Warnock DG;
Am J Kidney Dis; 2003 Mar; 41(3):651-7. PubMed ID: 12612989
[TBL] [Abstract][Full Text] [Related]
4. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Coyne DW; Adkinson NF; Nissenson AR; Fishbane S; Agarwal R; Eschbach JW; Michael B; Folkert V; Batlle D; Trout JR; Dahl N; Myirski P; Strobos J; Warnock DG;
Kidney Int; 2003 Jan; 63(1):217-24. PubMed ID: 12472786
[TBL] [Abstract][Full Text] [Related]
5. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease.
Ganguli A; Kohli HS; Khullar M; Lal Gupta K; Jha V; Sakhuja V
Ren Fail; 2009; 31(2):106-10. PubMed ID: 19212906
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
Panesar A; Agarwal R
Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
[TBL] [Abstract][Full Text] [Related]
7. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
8. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
9. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
10. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
11. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
13. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
14. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
15. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
17. On the relative safety of parenteral iron formulations.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2004 Jun; 19(6):1571-5. PubMed ID: 15150356
[TBL] [Abstract][Full Text] [Related]
18. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
19. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
20. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
Warady BA; Zobrist RH; Wu J; Finan E;
Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
